Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.